Keywords: valeant, 1st-qtr, loss, deepens, 4m, usa-based, pharmaceuticals
Valeant 1st-qtr 2006 loss deepens to $6.4M
Article | 15 May 2006
USA-based Valeant Pharmaceuticals says that, in the first quarter of 2006, revenues increased 10% on the like, year-ago period to $198.8 million, led ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
